Inflammatory activity and vitamin D levels in an MS population treated with rituximab.
Johan LindenGabriel GranåsenJonatan SalzerAnders SvenningssonPeter SundströmPublished in: Multiple sclerosis journal - experimental, translational and clinical (2019)
The inflammatory activity in this rituximab-treated multiple sclerosis population that increasingly used vitamin D supplementation was extremely low. Higher 25-hydroxy-vitamin D levels were associated with beneficial outcomes.